Trials / Completed
CompletedNCT05497635
A Study of STSA-1002 in Healthy Subjects
A Randomized,Double-blind, Placebo-controlled, Multiple Ascending-Dose Phase Ib Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of STSA-1002 Injection in Healthy Subjects
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 26 (actual)
- Sponsor
- Staidson (Beijing) Biopharmaceuticals Co., Ltd · Industry
- Sex
- All
- Age
- 18 Years – 45 Years
- Healthy volunteers
- Accepted
Summary
This study is a Phase Ib, randomized, double-blind, placebo-controlled, multiple dose, dose escalation safety, tolerability,pharmacokinetic and pharmacodynamic study of STSA-1002 injection in healthy subjects. A total of 26 healthy subjects were enrolled in three dosage groups.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | STSA-1002 Injection | Intravenous injection |
| DRUG | Placebo | Intravenous injection |
Timeline
- Start date
- 2022-10-14
- Primary completion
- 2023-04-06
- Completion
- 2023-04-06
- First posted
- 2022-08-11
- Last updated
- 2023-04-18
Locations
2 sites across 1 country: China
Source: ClinicalTrials.gov record NCT05497635. Inclusion in this directory is not an endorsement.